Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px

Document › Details

MorphoSys AG. (4/11/17). "Press Release: MorphoSys to Present at Upcoming Conferences". Planegg-Martinsried.

	Region	New York, NY
	Country	United States (USA)
	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Organisation 2	Kempen & Co. N.V.
	Group	Van Lanschot (Group)
	Product	Berenberg European Conference USA
	Product 2	UBS Global Healthcare Conference 2017 New York
	Index term	MorphoSys–Van Lanschot: investor conference, 201704 supply service MorphoSys presents at Kempen Life Sciences Conference
	Index term 2	MorphoSys–UBS: investor conference, 201705 supply service MorphoSys presents at UBS Global Healthcare Conference NY
	Person	Holstein, Jens (BioNTech 202107– CFO before MorphoSys 201105–202012 CFO before Fresenius Kabi)
	Person 2	Moroney, Simon E. (MorphoSys 1992–201908 CEO + Founder STEPPED DOWN 9/19)

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

10th Kempen Life Sciences Conference
Date: April 19, 2017
Venue: Amsterdam, Netherlands
Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG

UBS Global Healthcare Conference
Date: May 22/23, 2017
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

Berenberg European Conference
Date: May 24, 2017
Venue: Tarrytown, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG

A PDF version of the presentation will be provided at www.morphosys.com.

The Annual General Meeting of MorphoSys AG will take place on May 17, 2017 in Munich. A live webcast of the event and all related information are available on www.morphosys.com/agm.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Record changed: 2023-06-05